clinical trial · NCT07449234
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Psoriasis
brief summary
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
started
Feb 9, 2026
primary completion
Mar 15, 2027
completion
Sep 1, 2027
last updated
May 8, 2026
official title
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol